Hyppää pääsisältöön

Varje öre räknas verkligen.

Ge En Gåva

Olet täällä

Neuvoa-antava komitea

Neuvoa-antava komitea koostuu erilaisista eri tutkimusalojen asiantuntijoista, jotka yhdessä tekevät valtavan työn vuosittaisten tutkimusapurahojen hakemusten käsittelyssä. Asiantuntijaryhmä tarkistaa kaikki saapuvat hakemukset ja arvottaa ne säännöstön mukaisesti. Neuvoa-antava komitea suosittelee säätiön hallituksen tutkimushankkeita, jotka soveltuvat heidän mielestään apurahojen saajiksi. 

Lue lisää siitä, miten työskentely etenee ja kuinka ne tutkimushankkeet valitaan, jotka neuvoa-antava komitea katsoo sopivan parhaiten säätiön tutkimusstrategian kanssa ja ne tutkimushankkeet valitaan, joilla heidän mielestään on parhaat edellytykset kehittää hoitometodeja tyypin 1 ja tyypin 2 potilaille. 

Neuvoa-antava komitea koostuu seuraavista henkilöistä:


Professor Christian Berne

Neuvoa-antavan komitean puheenjohtaja
Christian Berne on lääketieteen professori, sisätautien ja endokrinologian erikoislääkäri, diabeteksen ja hormonitoiminnan ylilääkäri Akademiska sjukhuset, Uppsala.

Christian Berne väitteli vuonna 1974. Hänestä tuli histologian dosenttu vuonna 1974 ja lääketieteen dosenttii vuonna 1982. Hänet nimitettiin professoriksi Uppsalan yliopistossa 1999.

Christian Berne työskentelee kliinisen diabetestutkimuksen kanssa, viime vuosina hän on keskittynyt tyypin 2 diabetekseen. 


Professor Paul Johnson, MBChB MD FRCS

Director of Oxford Islet Transplant Programme and Professor of Paediatric Surgery, University of Oxford.

Paul Johnson qualified in medicine from the University of Leicester and subsequently trained in General Surgery in Leicester and Derby, followed by higher surgical training in Paediatric Surgery in Oxford, Melbourne, and Great Ormond Street Hospital in London.

Between 1993 and 1996 he was a Research Fellow in the Department of Surgery at the University of Leicester, where he undertook a project on the Isolation of Human Islets of Langerhans for Pancreatic Islet Transplantation. This led to a Doctorate of Medicine and started his ongoing interest in the field of Islet Transplantation for reversing Type 1 Diabetes. He was awarded a Hunterian Professorship from the Royal College of Surgeons of England for this research in 1998.

In 2002, Mr Johnson was appointed Director of the Islet Transplant Programme in Oxford. He is currently Chairman of the Research division of British Association of Paediatric Surgeons Research and Clinical Effectiveness Committee, Founder of the UK Academic Paediatric Surgeons Group and Co-Secretary of the International Pancreas and Islet Transplantation Association. He is also Clinical Tutor at St Edmund Hall.

He has an active research group and his research interests include ways of optimizing the current methods used for islet isolation with particular reference to pancreatic structure and collagenase, and the developmental biology of the pancreas and foregut with particular relevance to the use of adult stem cells as an alternative source of islet tissue for transplantation.

In addition to islet transplantation, his clinical interests include the neonatal and paediatric pancreas (endocrine and exocrine), as well as other aspects of paediatric surgical gastroenterology.


Dr Julian Paul Hamilton-Shield MB,ChB, MD(Bristol), MRCP, FRCPCH

Senior Lecturer, University of Bristol.

Julian Shield qualified in 1985 and undertook his post-graduate training in Bristol and London. His early research mainly centered on Type 1 diabetes and rare forms of inherited diabetes. The epidemic of childhood obesity in the UK prompted a re-alignment of research interests to include the prevention and treatment of Type 2 diabetes and the "Metabolic Syndrome" in childhood. His clinical practice in diabetes, endocrinology and metabolism is based in one of the few, purpose built children’s hospitals in the United Kingdom. He is currently a Senior Lecturer in child health at the University of Bristol.


Professor Ulf Smith

Principal Investigator

Professor Smith is an expert in the pathogenesis of insulin resistance and type 2 diabetes. He focuses primarily on the role of adipose tissue in insulin resistance and the factors that contribute to the increase in cardiovascular diseases in patients with insulin resistance. He is Director of the Lundberg Laboratory and President of the European Association for the Study of Diabetes.

His research team focuses on the role of the adipose tissue in eliciting insulin resistance as well as the associated increase in cardiovascular morbidity and mortality. They have developed a broad methodological platform involving state-of-the-art technologies for phenotyping humans and experimental models involving transgenic animals or appropriate cell lines.

His team has coordinated two major EU-funded projects and is currently involved in other EU-funded projects.


Professor Patrik Rorsman

Professor of Diabetic Medicine and Professorial Fellow of Harris Manchester College, University of Oxford

Patrik Rorsman studied medicine at Uppsala University, Sweden where he also obtained in PhD in 1986. He moved to the University of Gothenburg in 1987 to become an independent investigator, where he held a series of Medical Research council-supported fellowship. In 1994 he became Director of Islet Research at Novo Nordisk in Copenhagen. He returned to academia in 1997 when he became Professor of Membrane Physiology at Lund University, where he remained until 2003 when he was elected Professor of Diabetic Medicine at the University of Oxford where he currently directs the work of a team of ~15 postdoctoral scientists.

Professor Rorsman’s research focuses on the cellular control of pancreatic hormone secretion, how these processes become impaired in diabetes and their correction by therapeutic interventions.

He has published more than 200 original publications, several of which have appeared in leading journals like Nature and Science.

Professor Rorsman’s work has been recognised by several international awards including the Minkowski Prize of the European Association for the Study of diabetes in 1996. He became a Member of Academia Europea in 2007 and a Fellow of the Academy of Medical Science (FMedSci) in 2010.


Professor Jan Eriksson

MD, PhD, Full Professor and Chair in Clinical Diabetes and Metabolism, Dept of Medical Sciences, Uppsala University Hospital. Board-certified specialist in Internal Medicine and Endocrinology. Senior Consultant Physician and Head of the Section of Endocrinology and Diabetes at Uppsala University Hospital

Clinical, scientific and educational experience

During more than 30 years several positions as physician, mainly as specialist in diabetology and endocrinology at University Hospitals in Göteborg, Lund, Umeå and Uppsala in Sweden. These include senior leadership roles such as Head of Department and Head of Research Units. During the same time period research in experimental and clinical diabetology and metabolism, mainly as a research group leader. Focus on mechanisms of insulin resistance, in particular translational aspects. Author of approx. 160 scientific papers, most of them published in international scientific journals. Coauthor of textbooks on type 2 diabetes and on vascular diseases.

Long-standing experience as lecturer and tutor for graduate and post-graduate medical students and for PhD students and post doc fellows. Supervisor for 12 PhD thesis projects. Recently returned to full-time academic work at Uppsala University, leading a research group that mainly focuses on the role of adipose tissue in diabetes and diabetic complications.

Industry experience

Many years of part-time assignments with major pharmaceutical companies, involving expert consultancies, advisory boards, steering committees for clinical trials and education. During 10 years, 2003-2013, full-time senior research positions within AstraZeneca R&D. These have included Disease Area Medical Expert in diabetes and dyslipidemia and Senior Principal Scientist. Most recently, 2007-2013, Medical Science Director in Clinical Development, Diabetes and Obesity as well as in Clinical Discovery. Leader of a large group of MDs, PhDs and other scientists that was responsible for translational and early clinical research in numerous drug projects. Clinical representative in diabetes/obesity Strategy Team. PI or co-PI for several internal and external scientific networks and collaborations, for example focusing on: adipose tissue mechanisms and markers of insulin resistance; markers of beta cell function and mass in diabetes; regulation of cardiac lipid metabolism. During the period of industry research also continuous part-time appointments as Professor in Internal Medicine or Clinical Diabetology at the Umeå, Gothenburg and Uppsala Universities, respectively.


Dr Leif Groop

Leif Groop, M.D., Ph.D. is, since 1993, Professor in Endocrinology at Lund University and Director of Lund University Diabetes Centre. He received his MD at University of Berne, Switzerland and PhD at University of Helsinki, Finland. After a postdoc period at Yale University he devoted his research to dissection of the heterogeneity of diabetes but also to explore the pathogenic events leading to type 2 diabetes.

As an important tool to achieve this goal, he initiated the Botnia Study at the west coast of Finland, one of the world’s largest family studies on type 2 diabetes. The research group has been involved in many of the genetic discoveries on type 2 diabetes during the past 15 years, including one of the first whole genome association studies for type 2 diabetes. He is a member of the Swedish Royal Academy of Science. He has served on numerous editorial boards and achieved several international recognitions, including the Claude Bernard, Anders Jahre and Fernströms awards.


Professor Paul Franks

Paul trained in genetic epidemiology and biostaistics at the University of Cambridge in the UK and at the Epidemiology and Clincial Research Branch of the National Institutes of Diabetes and Digestive and Kidney Disease (NIDDK) in the USA.  In 2010, Paul was appointed full professor in genetic epidemiology and head of the Genetic and Molecular Epidemiology (GAME) Unit at Lund University Diabetes Center in Malmö, Sweden.  The GAME Unit is comprised of >20 administrative staff, graduate students, post-docs, and junior faculty. Paul is also an adjunct professor at Harvard University in Boston, Massachusetts and a professor in molecular epidemiology at Umeå University in Sweden. He is also a Fellow of the Obesity Society.

Whilst working in Umeå (2006-2010), Paul established the GLACIER Study, a prospective cohort study of 20,000 adults from Northern Sweden funded by the Swedish Research Council and nested in the Northern Sweden Biobank. Paul is internationally recognized for his research on gene-environment interactions in type 2 diabetes, CVD and obesity, having received awards for his research from the European Associaiton for the Study of Diabetes, Association for the Study of Obesity, American College of Sports Medicine, amongst others. He has authored >200 publications in and around the topic of gene-envrionment interactions. Paul has been a member of numerous editorial boards, and currently serves as Associate Editor for the journals Obesity, BMC Medical Genetics, and Frontiers in Genetic Epidemiology, he is also Assistant Editor-in-Chief and Section Editor (Public Health & Translational Medicine) for Current Nutrition Reports. Paul is currently the Principle Investigator on grants from the National Institutes of Health (USA), the EU’s Innovative Medicine’s Innitiative, the Swedish Research Council, Swedish Diabetes Association, Novo Nordisk Foundation, and other major funding agencies.


Dr Erik Gylfe

Erik Gylfe PhD started medical studies Umeå University in 1968 where he got his PhD in 1974. He moved to Uppsala University in 1976 and made a postdoctoral period at University of Pennsylvania, Philadelphia in 1979. He then held various positions at the Swedish Research Council and Uppsala University where he was appointed Professor of Secretion Research at the Department of Medical Cell Biology in 1994, became Chairman in 2009 and Emeritus in 2014.

His research has focussed on signal transduction of hormone secretion in particular the blood glucose-regulating hormones insulin and glucagon. Apart from authoring more than 200 scientific publications he supervised 18 theses dealing with islet hormone secretion and 6 about parathyroid hormone secretion. A common denominator in Gylfe’s expertise is various cell physiological and cell biological approaches for studying intracellular messenger kinetics and secretion at the level of single cells that are either isolated or located in their natural environment (e.g. within the pancreatic islet). He pioneered studies of Ca2+ signalling and demonstrated that Ca2+ oscillations underlie pulsatile insulin release. More recent studies involve oscillatory signalling of other messengers like cAMP and the mechanisms that determine phase relationships between pulsatile release of insulin, somatostatin and glucagon.


Professor Unn-Britt Johansson

Unn-Britt Johansson, is professor in Nursing Science at Sophiahemmet University and at Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden. She is also Chairman, Board of Education at Sophiahemmet University and Chairman, Board of the National Clinical Final Examination of Bachelor´s programme in Nursing, Sweden. She has been a RN since 1989 and and started her research in 1997 and finished her doctoral

degree in 2000 at Karolinska Institutet. Her main research interest is patient education, psychosocial support for persons living with diabetes and development and evaluation of questionnaires. She is supervisor for several doctoral students. Currently she is also programme leader for the specialist nursing program in diabetes care (also leading to a Masters Degree in Nursing Science). Unn-Britt is also a member in FEND Executive Committee and since 2013 member of Diabetes Education Consultative Section (DECS) of the International Diabetes Federation (IDF). 


Dr Nicholas Timpson University of Bristol, England

Dr Mike Weedon University of Exeter, England 

Dr Gunilla Westermark